T-cell redirecting bispecific antibodies for treatment of disease
First Claim
1. A method of inducing a T-cell mediated cytotoxic immune response against a Trop-2 positive human cancer cell comprising:
- a) administering a T-cell redirecting complex, comprising at least one binding site for human CD3 and at least one binding site for human Trop-2, to a subject to induce a T-cell mediated immune response against the Trop-2 positive human cancer cell and wherein the T-cell redirecting complex comprises;
(i) a first antibody moiety conjugated to an AD (anchoring domain) moiety from an AKAP protein; and
(ii) a second antibody moiety conjugated to a DDD (dimerization and docking domain) moiety, wherein the amino acid sequence of said DDD moiety is residues 1-44 of human protein kinase A (PKA) RIIα
wherein two copies of the DDD moiety form a dimer that binds to one copy of the AD moiety to form the complex after “
human cancer cell”
.
1 Assignment
0 Petitions
Accused Products
Abstract
The present invention concerns compositions and methods of use of T-cell redirecting complexes, with at least one binding site for a T-cell antigen and at least one binding site for an antigen on a diseased cell or pathogen. Preferably, the complex is a DNL™ complex. More preferably, the complex comprises a bispecific antibody (bsAb). Most preferably, the bsAb is an anti-CD3×anti-CD19 bispecific antibody, although antibodies against other T-cell antigens and/or disease-associated antigens may be used. The complex is capable of targeting effector T cells to induce T-cell-mediated cytotoxicity of cells associated with a disease, such as cancer, autoimmune disease or infectious disease. The cytotoxic immune response is enhanced by co-administration of interferon-based agents that comprise interferon-α, interferon-β, interferon-λ1, interferon-λ2 or interferon-λ3.
-
Citations
10 Claims
-
1. A method of inducing a T-cell mediated cytotoxic immune response against a Trop-2 positive human cancer cell comprising:
a) administering a T-cell redirecting complex, comprising at least one binding site for human CD3 and at least one binding site for human Trop-2, to a subject to induce a T-cell mediated immune response against the Trop-2 positive human cancer cell and wherein the T-cell redirecting complex comprises;
(i) a first antibody moiety conjugated to an AD (anchoring domain) moiety from an AKAP protein; and
(ii) a second antibody moiety conjugated to a DDD (dimerization and docking domain) moiety, wherein the amino acid sequence of said DDD moiety is residues 1-44 of human protein kinase A (PKA) RIIα
wherein two copies of the DDD moiety form a dimer that binds to one copy of the AD moiety to form the complex after “
human cancer cell”
.- View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10)
Specification